Belgian Cancer Registry

CANCER FACT SHEET 2024
CANCER OF THE BILIARY SYSTEM
ICD-10 C22-C24

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from the Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Cancer of the biliary system incidence: by region 5

1.1.1. Cancer of the biliary system incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Cancer of the biliary system incidence: by tumour type 7

1.2.1. Cancer of the biliary system incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.3. Cancer of the biliary system incidence: by tumour location and tumour type and tumour stage 8

1.3.1. Cancer of the biliary system incidence by location, type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

2. CANCER INCIDENCE TRENDS 10

2.1. Cancer of the biliary system incidence trends: by region 10

2.1.1. Cancer of the biliary system incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 10

2.1.2. Cancer of the biliary system incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 12

2.2. Cancer of the biliary system incidence trends: by tumour type 13

2.2.1. Cancer of the biliary system incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 13

2.3. Cancer of the biliary system incidence trends: by tumour location and tumour type and tumour stage 15

2.3.1. Cancer of the biliary system incidence trends by location, type, stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 15

2.4. Cancer of the biliary system incidence trends: by age group 20

2.4.1. Cancer of the biliary system incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 20

2.4.2. Cancer of the biliary system incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 21

3. CANCER PREVALENCE 22

3.1. Cancer of the biliary system prevalence: by region 22

3.1.1. Cancer of the biliary system prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 22

4. CANCER SURVIVAL 23

4.1. Cancer of the biliary system survival: by region 23

4.1.1. Cancer of the biliary system survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024 23

4.2. Cancer of the biliary system survival: by tumour type 25

4.2.1. Cancer of the biliary system survival by type and sex: number at risk and net survival probabilities, 2015-2024 25

4.3. Cancer of the biliary system survival: by tumour location and tumour type and tumour stage 26

4.3.1. Cancer of the biliary system survival by location, type, stage and sex: number at risk and net survival probabilities, 2015-2024 26
5. CANCER SURVIVAL TRENDS 29
5.1. Cancer of the biliary system survival trends: by tumour type 29
5.1.1. Cancer of the biliary system survival trends by type and sex: number at risk and net survival probabilities, 2004-2024 29
5.2. Cancer of the biliary system survival trends: by tumour location and tumour type and tumour stage 31
5.2.1. Cancer of the biliary system survival trends by location, type, stage and sex: number at risk and net survival probabilities, 2004-2024 31
6. CANCER MORTALITY 36
6.1. Cancer of the biliary system mortality: by region 36
6.1.1. Cancer of the biliary system mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 36
7. CANCER MORTALITY TRENDS 38
7.1. Cancer of the biliary system mortality trends: by region 38
7.1.1. Cancer of the biliary system mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 38
7.1.2. Cancer of the biliary system mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 40

1.1. Cancer of the biliary system incidence: by region

1.1.1. Cancer of the biliary system incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	3	0	0	0	1	4	2	4	7	10	31	71	147	203	256	204	141	69	21	5	1,179	21.3
	[1.0]	[0.0]	[0.0]	[0.0]	[0.3]	[1.1]	[0.5]	[1.1]	[1.8]	[2.7]	[7.9]	[17.8]	[38.7]	[62.5]	[95.3]	[95.8]	[111.4]	[84.0]	[64.4]	[78.4]	[20.3]	(20.1; 22.6)
Brussels	0	0	0	0	0	0	0	2	0	2	4	10	11	19	18	13	9	7	3	0	98	25.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[4.2]	[0.0]	[4.5]	[9.7]	[27.6]	[37.2]	[87.4]	[106.0]	[101.0]	[109.4]	[138.2]	[133.6]	[0.0]	[16.0]	(20.2; 30.5)
Flanders	1	0	0	0	0	2	2	2	4	6	12	31	77	101	142	109	87	41	13	4	634	18.4
	[0.6]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[0.9]	[0.9]	[1.8]	[2.8]	[5.3]	[13.0]	[33.1]	[50.3]	[85.5]	[80.7]	[103.9]	[73.7]	[59.4]	[95.0]	[18.8]	(16.9; 19.8)
Wallonia	2	0	0	0	1	2	0	0	3	2	15	30	59	83	96	82	45	21	5	1	447	26.4
	[2.1]	[0.0]	[0.0]	[0.0]	[0.9]	[1.8]	[0.0]	[0.0]	[2.6]	[1.7]	[11.9]	[24.3]	[50.0]	[81.1]	[112.3]	[126.1]	[130.2]	[97.9]	[59.0]	[62.3]	[24.7]	(23.9; 28.9)
Females																						
Belgium	2	0	1	3	0	1	3	5	6	13	24	32	50	91	90	111	96	58	17	4	607	9.3
	[0.7]	[0.0]	[0.3]	[0.9]	[0.0]	[0.3]	[0.8]	[1.3]	[1.6]	[3.5]	[6.2]	[8.1]	[13.0]	[26.4]	[30.1]	[43.4]	[55.2]	[42.8]	[23.6]	[18.5]	[10.2]	(8.6; 10.0)
Brussels	0	0	0	1	0	0	0	1	1	1	2	2	5	7	8	9	8	6	1	0	52	10.3
	[0.0]	[0.0]	[0.0]	[2.7]	[0.0]	[0.0]	[0.0]	[2.1]	[2.2]	[2.4]	[5.2]	[5.8]	[16.4]	[27.8]	[37.2]	[48.5]	[62.5]	[62.2]	[17.7]	[0.0]	[8.2]	(7.5; 13.1)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	1	0	1	2	0	0	1	4	1	6	9	17	36	45	55	56	64	30	9	3	340	8.6
	[0.6]	[0.0]	[0.5]	[1.1]	[0.0]	[0.0]	[0.5]	[1.9]	[0.4]	[2.8]	[4.1]	[7.3]	[15.5]	[21.8]	[31.0]	[36.2]	[58.4]	[34.6]	[19.9]	[23.3]	[9.9]	(7.7; 9.5)
Wallonia	1	0	0	0	0	1	2	0	4	6	13	13	9	39	27	46	24	22	7	1	215	10.4
	[1.1]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[1.7]	[0.0]	[3.4]	[5.1]	[10.4]	[10.4]	[7.3]	[34.5]	[27.0]	[55.6]	[46.6]	[56.2]	[33.2]	[15.1]	[11.4]	(9.0; 11.8)

1.2. Cancer of the biliary system incidence: by tumour type

1.2.1. Cancer of the biliary system incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
Cholangiocarcinoma	40 [1.2]	151 [15.5]	122 [26.5]	313 [5.4]	5.7 (5.1; 6.3)	42 [1.3]	111 [10.8]	96 [14.6]	249 [4.2]	3.9 (3.4; 4.4)
Hepatocellular carcinoma	69 [2.0]	369 [37.9]	242 [52.5]	680 [11.7]	12.3 (11.3; 13.2)	25 [0.7]	56 [5.4]	81 [12.3]	163 [2.7]	2.5 (2.1; 2.9)
Adenocarcinoma	14 [0.4]	68 [7.0]	53 [11.5]	135 [2.3]	2.4 (2.0; 2.9)	17 [0.5]	57 [5.5]	75 [11.4]	149 [2.5]	2.3 (1.9; 2.7)
Other and unspecified	7 [0.2]	18 [1.8]	23 [5.0]	51 [0.9]	0.9 (0.7; 1.2)	3 [0.1]	7 [0.7]	34 [5.2]	46 [0.8]	0.7 (0.5; 0.9)

1.3. Cancer of the biliary system incidence: by tumour location and tumour type and tumour stage

1.3.1. Cancer of the biliary system incidence by location, type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
Hepatic Cholangiocarcinoma	**I**	3 [0.1]	22 [2.3]	9 [2.0]	34 [0.6]	0.6 (0.4; 0.8)	2 [0.1]	8 [0.8]	5 [0.8]	15 [0.3]	0.2 (0.1; 0.3)
	II	1 [0.0]	10 [1.0]	8 [1.7]	19 [0.3]	0.4 (0.2; 0.5)	5 [0.1]	5 [0.5]	9 [1.4]	19 [0.3]	0.3 (0.2; 0.4)
	III	1 [0.0]	8 [0.8]	19 [4.1]	28 [0.5]	0.5 (0.3; 0.7)	7 [0.2]	12 [1.2]	11 [1.7]	30 [0.5]	0.5 (0.3; 0.6)
	IV	17 [0.5]	61 [6.3]	43 [9.3]	121 [2.1]	2.2 (1.8; 2.5)	22 [0.7]	51 [5.0]	30 [4.6]	103 [1.7]	1.7 (1.3; 2.0)
	X/NA	1 [0.0]	6 [0.6]	6 [1.3]	13 [0.2]	0.3 (0.1; 0.4)	2 [0.1]	4 [0.4]	4 [0.6]	10 [0.2]	0.2 (0.1; 0.2)
Cholangiocarcinoma of gallbladder & biliary tract	**X/NA**	17 [0.5]	44 [4.5]	37 [8.0]	98 [1.7]	1.8 (1.4; 2.2)	4 [0.1]	31 [3.0]	37 [5.6]	72 [1.2]	1.1 (0.8; 1.3)
Hepatocellular carcinoma	**I**	19 [0.6]	117 [12.0]	60 [13.0]	196 [3.4]	3.5 (3.0; 4.0)	14 [0.4]	23 [2.2]	19 [2.9]	57 [1.0]	0.9 (0.7; 1.1)
	II	22 [0.7]	81 [8.3]	49 [10.6]	152 [2.6]	2.7 (2.3; 3.1)	4 [0.1]	13 [1.3]	13 [2.0]	30 [0.5]	0.5 (0.3; 0.6)
	III	15 [0.4]	80 [8.2]	48 [10.4]	143 [2.5]	2.6 (2.2; 3.0)	4 [0.1]	9 [0.9]	18 [2.7]	31 [0.5]	0.5 (0.3; 0.6)
	IV	11 [0.3]	65 [6.7]	67 [14.5]	143 [2.5]	2.6 (2.2; 3.0)	3 [0.1]	6 [0.6]	28 [4.2]	37 [0.6]	0.5 (0.4; 0.7)
	X/NA	2 [0.1]	26 [2.7]	18 [3.9]	46 [0.8]	0.8 (0.6; 1.1)	0 [0.0]	5 [0.5]	3 [0.5]	8 [0.1]	0.1 (0.0; 0.2)
Adenocarcinoma of gallbladder & biliary tract	**I**	3 [0.1]	13 [1.3]	11 [2.4]	27 [0.5]	0.5 (0.3; 0.7)	3 [0.1]	2 [0.2]	8 [1.2]	13 [0.2]	0.2 (0.1; 0.3)
	II	3 [0.1]	8 [0.8]	7 [1.5]	18 [0.3]	0.3 (0.2; 0.5)	5 [0.1]	16 [1.6]	11 [1.7]	32 [0.5]	0.5 (0.3; 0.7)
	III	3 [0.1]	13 [1.3]	7 [1.5]	23 [0.4]	0.4 (0.2; 0.6)	2 [0.1]	9 [0.9]	25 [3.8]	36 [0.6]	0.5 (0.4; 0.7)
	IV	2 [0.1]	15 [1.5]	10 [2.2]	27 [0.5]	0.5 (0.3; 0.7)	6 [0.2]	23 [2.2]	20 [3.0]	49 [0.8]	0.8 (0.5; 1.0)
	X/NA	2 [0.1]	14 [1.4]	15 [3.3]	31 [0.5]	0.6 (0.4; 0.8)	0 [0.0]	6 [0.6]	11 [1.7]	17 [0.3]	0.3 (0.1; 0.4)
Other and unspecified	**I**	1 [0.0]	6 [0.6]	6 [1.3]	13 [0.2]	0.2 (0.1; 0.4)	0 [0.0]	1 [0.1]	3 [0.5]	4 [0.1]	0.1 (0.0; 0.1)
	II	0 [0.0]	1 [0.1]	2 [0.4]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	4 [0.6]	4 [0.1]	0.1 (0.0; 0.1)
	III	2 [0.1]	5 [0.5]	3 [0.7]	10 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	2 [0.2]	3 [0.5]	6 [0.1]	0.1 (0.0; 0.2)

Type	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
	IV	1 [0.0]	7 [0.7]	4 [0.9]	12 [0.2]	0.2 (0.1; 0.3)	2 [0.1]	1 [0.1]	12 [1.8]	15 [0.3]	0.2 (0.1; 0.3)
	X/NA	4 [0.1]	4 [0.4]	11 [2.4]	22 [0.4]	0.4 (0.2; 0.6)	1 [0.0]	4 [0.4]	12 [1.8]	19 [0.3]	0.3 (0.2; 0.4)

2.1. Cancer of the biliary system incidence trends: by region

2.1.1. Cancer of the biliary system incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	412	437	501	541	600	581	685	741	791	802	804	890	938	960	967	1,090	1,002	1,045	1,129	1,149	1,179		
	CR	8.1	8.5	9.7	10.4	11.5	11.0	12.9	13.8	14.6	14.7	14.7	16.2	16.9	17.2	17.3	19.4	17.7	18.4	19.8	19.9	20.3		
	ESR2013	10.0	10.4	11.9	12.6	13.8	12.9	15.4	16.1	16.9	17.0	16.7	18.5	19.1	19.2	19.0	21.2	19.2	19.9	21.0	21.0	21.3	3.9 (3.5; 4.2)	2004-2024
																							6.9 (5.7; 8.2)	2004-2011
																							3.4 (1.6; 5.2)	2012-2015
																							1.7 (0.9; 2.6)	2016-2024
Brussels	**N**	27	40	49	47	49	62	78	66	89	72	74	74	78	97	74	87	84	80	101	100	98		
	CR	5.6	8.3	10.0	9.5	9.7	12.0	14.8	12.2	16.1	12.8	13.1	12.9	13.5	16.7	12.6	14.7	14.1	13.4	16.8	16.4	16.0		
	ESR2013	8.2	11.5	14.9	13.9	14.7	17.2	21.6	18.7	24.2	20.0	20.6	20.0	21.2	26.8	19.2	22.8	22.3	20.3	26.1	24.2	25.3	4.5 (3.6; 5.4)	2004-2024
																							11.4 (8.2; 14.7)	2004-2011
																							1.0 (-0.5; 2.4)	2012-2024
Flanders	**N**	233	249	272	285	332	319	364	388	403	418	390	455	496	479	514	566	531	541	601	631	634		
	CR	7.9	8.4	9.1	9.4	10.9	10.4	11.8	12.5	12.9	13.3	12.3	14.3	15.5	14.9	15.9	17.4	16.2	16.4	18.1	18.8	18.8		
	ESR2013	9.2	9.7	10.7	11.0	12.6	11.6	13.3	13.7	14.0	14.4	13.1	15.3	16.4	15.6	16.3	17.8	16.3	16.6	18.0	18.5	18.4	3.6 (3.1; 4.0)	2004-2024
																							6.2 (4.4; 8.0)	2004-2010

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
																							2.3 (0.2; 4.4)	2011-2014
																							2.6 (1.7; 3.4)	2015-2024
Wallonia	**N**	152	148	180	209	219	200	243	287	299	312	340	361	364	384	379	437	387	424	427	418	447		
	CR	9.3	9.0	10.9	12.5	13.1	11.8	14.3	16.7	17.3	18.0	19.5	20.6	20.7	21.8	21.4	24.6	21.7	23.8	23.8	23.2	24.7		
	ESR2013	11.8	11.4	13.5	15.3	16.1	14.4	17.8	20.2	21.1	21.2	23.2	24.7	23.7	24.9	24.6	27.7	24.2	26.3	26.2	25.0	26.4	4.3 (3.8; 4.7)	2004-2024
																							7.6 (6.6; 8.6)	2004-2014
																							1.1 (0.1; 2.0)	2015-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Cancer of the biliary system incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	294	326	322	334	388	418	422	440	431	457	486	469	490	475	565	492	550	574	568	585	607		
	CR	5.5	6.1	6.0	6.2	7.1	7.6	7.6	7.9	7.7	8.1	8.6	8.2	8.6	8.3	9.8	8.5	9.4	9.8	9.7	9.9	10.2		
	ESR2013	5.5	6.1	6.0	6.1	7.1	7.5	7.5	7.7	7.4	7.9	8.2	7.9	8.2	7.8	9.3	8.1	8.7	9.2	8.8	9.0	9.3	2.5 (2.2; 2.9)	2004-2024
																							5.1 (3.7; 6.4)	2004-2010
																							1.5 (1.0; 2.0)	2011-2024
Brussels	**N**	25	38	36	26	32	44	51	49	45	38	57	43	56	50	49	42	47	58	51	51	52		
	CR	4.8	7.3	6.8	4.9	5.9	8.0	9.1	8.5	7.7	6.4	9.6	7.1	9.2	8.2	8.0	6.8	7.6	9.3	8.2	8.1	8.2		
	ESR2013	5.0	7.6	7.5	5.7	6.8	9.5	10.7	10.0	9.0	7.9	12.2	8.7	11.6	10.2	9.3	8.7	9.3	11.8	10.4	10.4	10.3	3.0 (1.8; 4.2)	2004-2024
																							7.9 (3.9; 12.0)	2004-2011
																							0.4 (-1.4; 2.3)	2012-2024
Flanders	**N**	188	197	199	203	228	244	211	244	245	240	284	265	270	263	324	267	315	318	327	335	340		
	CR	6.2	6.4	6.5	6.5	7.3	7.8	6.7	7.6	7.6	7.4	8.8	8.1	8.2	8.0	9.8	8.0	9.4	9.5	9.7	9.8	9.9		
	ESR2013	6.2	6.4	6.3	6.3	7.1	7.3	6.3	7.2	7.1	6.9	8.1	7.4	7.5	7.2	8.9	7.2	8.2	8.3	8.3	8.5	8.6	1.6 (1.1; 2.0)	2004-2024
Wallonia	**N**	81	91	87	105	128	130	160	147	141	179	145	161	164	162	192	183	188	198	190	199	215		
	CR	4.7	5.2	5.0	5.9	7.2	7.3	8.9	8.1	7.7	9.8	7.9	8.7	8.9	8.8	10.4	9.8	10.1	10.6	10.2	10.6	11.4		
	ESR2013	4.6	5.3	5.1	5.9	7.2	7.4	8.8	8.2	7.6	9.7	7.5	8.5	8.7	8.3	9.8	9.6	9.4	10.1	9.4	9.7	10.4	3.8 (3.2; 4.5)	2004-2024
																							8.5 (6.4; 10.6)	2004-2011
																							1.4 (0.5; 2.4)	2012-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Cancer of the biliary system incidence trends: by tumour type

2.2.1. Cancer of the biliary system incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Type		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
Cholangiocarcinoma	**N**	244	229	271	295	313			189	168	198	247	249		
	CR	4.3	4.0	4.7	5.1	5.4			3.2	2.9	3.4	4.2	4.2		
	ESR2013	4.6	4.4	5.0	5.4	5.7	5.7 (4.4; 7.0)	2004-2024	3.1	2.7	3.1	3.8	3.9	5.6 (4.3; 6.8)	2004-2024
							5.1 (4.0; 6.2)	2004-2022						4.9 (4.0; 5.8)	2004-2023
							11.0 (-2.5; 26.5)	2023-2024						19.0 (-5.7; 50.1)	2024-2024
Hepatocellular carcinoma	**N**	551	575	669	655	680			157	167	168	167	163		
	CR	9.7	10.1	11.7	11.4	11.7			2.7	2.9	2.9	2.8	2.7		
	ESR2013	10.5	10.9	12.4	11.9	12.3	4.6 (4.1; 5.1)	2004-2024	2.5	2.7	2.7	2.6	2.5	3.1 (2.4; 3.8)	2004-2024
							9.2 (7.7; 10.7)	2004-2012						7.9 (5.9; 10.0)	2004-2012
							2.4 (0.0; 4.8)	2013-2016						0.1 (-1.1; 1.3)	2013-2024
							1.3 (-0.1; 2.7)	2017-2024							
Adenocarcinoma	**N**	144	158	122	141	135			136	158	123	128	149		
	CR	2.5	2.8	2.1	2.4	2.3			2.3	2.7	2.1	2.2	2.5		
	ESR2013	2.8	3.1	2.3	2.6	2.4	-0.7 (-1.6; 0.3)	2004-2024	2.1	2.5	1.9	2.0	2.3	-0.6 (-1.4; 0.1)	2004-2024
							0.7 (-0.2; 1.7)	2004-2021							
							-8.2 (-14.2; -1.7)	2022-2024							
Other and unspecified	**N**	63	83	67	58	51			68	81	79	43	46		
	CR	1.1	1.5	1.2	1.0	0.9			1.2	1.4	1.3	0.7	0.8		
	ESR2013	1.2	1.6	1.3	1.1	0.9	2.6 (0.7; 4.5)	2004-2024	1.0	1.2	1.1	0.6	0.7	1.4 (0.0; 2.8)	2004-2024
							7.1 (3.3; 11.0)	2004-2015						5.2 (2.4; 8.0)	2004-2015

Type	Males							Females						
	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
						-2.7 (-7.0; 1.9)	2016-2024						-3.0 (-6.3; 0.3)	2016-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Cancer of the biliary system incidence trends: by tumour location and tumour type and tumour stage

2.3.1. Cancer of the biliary system incidence trends by location, type, stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Stage		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
Hepatic Cholangiocarcinoma															
I	**N**	11	21	16	30	34			15	15	16	20	15		
	CR	0.2	0.4	0.3	0.5	0.6			0.3	0.3	0.3	0.3	0.3		
	ESR2013	0.2	0.4	0.3	0.5	0.6	12.7 (8.8; 16.7)	2004-2024	0.3	0.3	0.3	0.3	0.2	12.9 (8.8; 17.1)	2004-2024
II	**N**	24	27	24	28	19			19	10	15	19	19		
	CR	0.4	0.5	0.4	0.5	0.3			0.3	0.2	0.3	0.3	0.3		
	ESR2013	0.5	0.5	0.4	0.5	0.4	12.3 (8.6; 16.0)	2004-2024	0.3	0.2	0.2	0.3	0.3	12.1 (8.8; 15.6)	2004-2024
														20.8 (12.0; 30.2)	2004-2013
														5.5 (-0.6; 12.0)	2014-2024
III	**N**	19	20	19	26	28			13	15	17	22	30		
	CR	0.3	0.4	0.3	0.5	0.5			0.2	0.3	0.3	0.4	0.5		
	ESR2013	0.4	0.4	0.4	0.5	0.5	5.2 (-1.8; 12.6)	2004-2024	0.2	0.2	0.2	0.3	0.5	1.9 (-2.3; 6.3)	2004-2024
							-18.2 (-31.1; -2.8)	2004-2013						-18.4 (-27.6; -7.9)	2004-2012
							29.1 (12.6; 48.0)	2014-2024						18.1 (9.5; 27.3)	2013-2024
IV	**N**	107	78	103	109	121			81	69	79	97	103		
	CR	1.9	1.4	1.8	1.9	2.1			1.4	1.2	1.3	1.6	1.7		
	ESR2013	2.0	1.5	1.9	2.0	2.2	13.9 (12.5; 15.2)	2004-2024	1.4	1.1	1.3	1.5	1.7	13.8 (12.2; 15.3)	2004-2024
							23.3 (19.3; 27.5)	2004-2012						24.6 (19.3; 30.2)	2004-2011
							7.9 (5.7; 10.2)	2013-2024						8.3 (6.0; 10.7)	2012-2024
X/NA	**N**	14	3	13	8	13			6	7	5	11	10		

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
	CR	0.2	0.1	0.2	0.1	0.2			0.1	0.1	0.1	0.2	0.2		
	ESR2013	0.3	0.1	0.2	0.2	0.3	-6.7 (-9.7; -3.6)	2004-2024	0.1	0.1	0.1	0.2	0.2	-4.9 (-8.0; -1.7)	2004-2024
							-0.9 (-6.6; 5.1)	2004-2016						5.2 (-2.7; 13.6)	2004-2013
							-14.8 (-22.4; -6.4)	2017-2024						-9.4 (-22.7; 6.1)	2014-2017
														-14.1 (-22.9; -4.5)	2018-2024
Cholangiocarcinoma of gallblader & biliary tract															
X/NA	**N**	68	80	95	93	98			55	52	65	78	72		
	CR	1.2	1.4	1.7	1.6	1.7			0.9	0.9	1.1	1.3	1.2		
	ESR2013	1.3	1.5	1.8	1.7	1.8	9.4 (6.3; 12.6)	2004-2024	0.9	0.8	1.0	1.2	1.1	6.5 (4.5; 8.5)	2004-2024
							16.3 (8.7; 24.3)	2004-2013							
							-4.8 (-17.0; 9.2)	2014-2017							
							9.5 (-0.2; 20.1)	2018-2024							
Hepatocellular carcinoma															
I	**N**	132	143	170	180	196			48	45	55	48	57		
	CR	2.3	2.5	3.0	3.1	3.4			0.8	0.8	0.9	0.8	1.0		
	ESR2013	2.5	2.7	3.1	3.3	3.5	11.6 (10.8; 12.5)	2004-2024	0.8	0.8	0.9	0.8	0.9	10.0 (8.1; 12.0)	2004-2024
							16.3 (13.9; 18.7)	2004-2012						31.5 (15.8; 49.3)	2004-2007
							8.6 (7.2; 10.0)	2013-2024						6.6 (4.8; 8.5)	2008-2024
II	**N**	126	113	144	183	152			31	30	39	32	30		
	CR	2.2	2.0	2.5	3.2	2.6			0.5	0.5	0.7	0.5	0.5		
	ESR2013	2.4	2.1	2.7	3.3	2.7	8.0 (6.2; 9.9)	2004-2024	0.5	0.5	0.6	0.5	0.5	8.2 (5.9; 10.5)	2004-2024
							15.0 (8.0; 22.6)	2004-2010						163.9 (72.4; 304.2)	2004-2005
							5.2 (2.7; 7.7)	2011-2024						3.2 (1.6; 4.8)	2006-2024
III	**N**	110	136	127	123	143			25	47	29	34	31		

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
	CR	1.9	2.4	2.2	2.1	2.5			0.4	0.8	0.5	0.6	0.5		
	ESR2013	2.1	2.6	2.4	2.3	2.6	5.3 (4.3; 6.3)	2004-2024	0.4	0.8	0.5	0.5	0.5	4.2 (1.1; 7.3)	2004-2024
IV	N	100	120	152	119	143			25	26	26	41	37		
	CR	1.8	2.1	2.7	2.1	2.5			0.4	0.4	0.4	0.7	0.6		
	ESR2013	2.0	2.3	2.8	2.1	2.6	9.3 (7.9; 10.7)	2004-2024	0.4	0.4	0.4	0.7	0.5	7.4 (4.4; 10.5)	2004-2024
							15.7 (11.5; 20.0)	2004-2012							
							5.3 (2.9; 7.7)	2013-2024							
X/NA	N	83	63	76	50	46			28	19	19	12	8		
	CR	1.5	1.1	1.3	0.9	0.8			0.5	0.3	0.3	0.2	0.1		
	ESR2013	1.6	1.2	1.4	0.9	0.8	-5.9 (-6.8; -5.0)	2004-2024	0.4	0.3	0.3	0.2	0.1	-7.3 (-8.0; -6.5)	2004-2024
							5.4 (3.6; 7.3)	2004-2016						5.0 (3.5; 6.6)	2004-2016
							-20.6 (-22.8; -18.4)	2017-2024						-23.1 (-24.9; -21.3)	2017-2024
Adenocarcinoma of gallblader & biliary tract															
I	N	19	11	19	22	27			12	19	20	16	13		
	CR	0.3	0.2	0.3	0.4	0.5			0.2	0.3	0.3	0.3	0.2		
	ESR2013	0.4	0.2	0.4	0.4	0.5	-1.9 (-3.6; -0.2)	2004-2024	0.2	0.3	0.3	0.2	0.2	-4.6 (-6.8; -2.4)	2004-2024
							-7.1 (-10.6; -3.5)	2004-2014						-10.0 (-14.1; -5.8)	2004-2015
							3.6 (-0.3; 7.7)	2015-2024						2.5 (-3.2; 8.6)	2016-2024
II	N	19	15	14	20	18			14	20	23	27	32		
	CR	0.3	0.3	0.2	0.3	0.3			0.2	0.3	0.4	0.5	0.5		
	ESR2013	0.4	0.3	0.3	0.4	0.3	-4.2 (-6.1; -2.2)	2004-2024	0.2	0.3	0.3	0.4	0.5	-1.4 (-3.1; 0.2)	2004-2024
														-5.7 (-7.6; -3.6)	2004-2019
														12.4 (4.3; 21.1)	2020-2024
III	N	23	23	29	38	23			26	28	25	36	36		

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
	CR	0.4	0.4	0.5	0.7	0.4			0.4	0.5	0.4	0.6	0.6		
	ESR2013	0.4	0.4	0.5	0.7	0.4	8.9 (5.9; 12.0)	2004-2024	0.4	0.5	0.4	0.6	0.5	7.8 (5.1; 10.6)	2004-2024
IV	N	21	26	15	22	27			26	43	27	34	49		
	CR	0.4	0.5	0.3	0.4	0.5			0.4	0.7	0.5	0.6	0.8		
	ESR2013	0.4	0.5	0.3	0.4	0.5	1.8 (0.1; 3.5)	2004-2024	0.4	0.7	0.4	0.5	0.8	2.4 (0.5; 4.4)	2004-2024
X/NA	N	49	60	30	20	31			44	37	17	13	17		
	CR	0.9	1.1	0.5	0.3	0.5			0.8	0.6	0.3	0.2	0.3		
	ESR2013	0.9	1.2	0.6	0.4	0.6	-3.0 (-4.9; -1.1)	2004-2024	0.6	0.6	0.3	0.2	0.3	-4.8 (-6.4; -3.1)	2004-2024
							2.9 (0.0; 5.9)	2004-2018						3.7 (0.9; 6.6)	2004-2017
							-15.5 (-21.7; -8.9)	2019-2024						-18.7 (-23.1; -14.1)	2018-2024
Other and unspecified															
I	N	7	9	7	6	13			5	5	6	1	4		
	CR	0.1	0.2	0.1	0.1	0.2			0.1	0.1	0.1	0.0	0.1		
	ESR2013	0.1	0.2	0.1	0.1	0.2	7.6 (3.6; 11.8)	2004-2024	0.1	0.1	0.1	0.0	0.1	1.7 (-2.3; 5.9)	2004-2024
II	N	5	9	7	6	3			6	8	7	3	4		
	CR	0.1	0.2	0.1	0.1	0.1			0.1	0.1	0.1	0.1	0.1		
	ESR2013	0.1	0.2	0.1	0.1	0.1	2.6 (-1.4; 6.8)	2004-2024	0.1	0.1	0.1	0.1	0.1	0.6 (-2.6; 3.9)	2004-2024
III	N	10	14	10	7	10			6	14	10	4	6		
	CR	0.2	0.2	0.2	0.1	0.2			0.1	0.2	0.2	0.1	0.1		
	ESR2013	0.2	0.3	0.2	0.1	0.2	4.4 (0.3; 8.7)	2004-2024	0.1	0.2	0.1	0.1	0.1	0.2 (-4.0; 4.6)	2004-2024
														-18.4 (-31.1; -3.5)	2004-2010
														7.7 (-12.4; 32.5)	2011-2014
														10.1 (0.9; 20.2)	2015-2024
IV	N	20	32	25	31	12			29	28	35	16	15		

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
	CR	0.4	0.6	0.4	0.5	0.2			0.5	0.5	0.6	0.3	0.3		
	ESR2013	0.4	0.6	0.5	0.6	0.2	6.5 (3.0; 10.1)	2004-2024	0.4	0.4	0.5	0.2	0.2	4.4 (1.9; 7.1)	2004-2024
X/NA	N	34	42	33	27	22			36	37	32	21	19		
	CR	0.6	0.7	0.6	0.5	0.4			0.6	0.6	0.5	0.4	0.3		
	ESR2013	0.6	0.8	0.7	0.5	0.4	-0.2 (-1.9; 1.5)	2004-2024	0.5	0.5	0.5	0.3	0.3	-1.3 (-2.5; -0.1)	2004-2024
							8.2 (4.9; 11.5)	2004-2016						4.8 (2.5; 7.1)	2004-2016
							-11.6 (-15.7; -7.2)	2017-2024						-9.8 (-12.8; -6.6)	2017-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Cancer of the biliary system incidence trends: by age group

2.4.1. Cancer of the biliary system incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	104	107	114	131	128	143	159	160	183	161	151	166	182	175	174	169	165	125	175	163	130		
	CR	3.3	3.3	3.5	4.0	3.9	4.4	4.8	4.8	5.5	4.8	4.5	5.0	5.5	5.2	5.2	5.1	4.9	3.7	5.2	4.8	3.8		
	ESR2013	3.5	3.5	3.7	4.2	4.1	4.5	5.0	5.0	5.6	4.9	4.5	4.9	5.4	5.1	5.1	4.9	4.8	3.6	5.1	4.8	3.8	1.1 (0.3; 2.0)	2004-2024
																							6.0 (3.2; 8.9)	2004-2011
																							0.3 (-3.6; 4.3)	2012-2015
																							-2.1 (-4.0; -0.2)	2016-2024
60-74	**N**	181	207	243	262	303	274	318	362	350	407	391	470	476	488	494	551	502	548	548	583	606		
	CR	26.6	30.2	35.4	37.4	42.5	37.7	42.9	47.9	45.5	52.0	49.1	57.8	57.2	57.0	56.2	61.3	54.8	58.6	58.0	60.8	62.3		
	ESR2013	26.4	30.1	35.3	37.5	43.2	38.1	44.2	48.6	46.2	53.4	49.9	59.9	58.9	58.3	57.2	62.5	55.6	59.8	59.1	61.9	63.8	3.7 (3.2; 4.2)	2004-2024
																							6.3 (5.3; 7.3)	2004-2015
																							0.6 (-0.6; 1.8)	2016-2024
75+	**N**	126	123	144	148	165	162	206	216	257	232	260	252	276	295	295	366	332	369	405	401	440		
	CR	43.0	40.6	45.9	45.4	49.0	46.9	58.2	59.8	69.6	61.7	67.8	64.4	69.9	74.7	74.3	90.6	80.3	88.7	93.9	90.1	95.5		
	ESR2013	39.2	37.3	43.5	44.2	46.6	44.1	57.2	57.2	66.7	58.4	64.8	63.2	68.7	73.3	72.5	88.6	79.3	87.8	92.3	88.7	95.0	4.8 (4.2; 5.3)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4.2. Cancer of the biliary system incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	55	59	44	56	63	74	70	74	89	77	74	70	71	76	94	73	90	81	68	83	87		
	CR	1.8	1.9	1.4	1.8	2.0	2.3	2.2	2.3	2.7	2.3	2.3	2.1	2.2	2.3	2.9	2.2	2.7	2.5	2.1	2.5	2.6		
	ESR2013	1.8	1.9	1.4	1.8	2.0	2.3	2.2	2.3	2.7	2.3	2.2	2.1	2.1	2.3	2.8	2.2	2.7	2.4	2.0	2.5	2.6	2.2 (1.1; 3.2)	2004-2024
																							5.6 (2.2; 9.1)	2004-2011
																							-1.8 (-6.5; 3.1)	2012-2015
																							1.3 (-1.0; 3.8)	2016-2024
60-74	**N**	107	129	132	132	143	154	154	162	144	166	184	187	198	180	215	205	183	238	214	232	231		
	CR	13.8	16.6	17.1	16.9	18.1	19.3	19.0	19.7	17.3	19.6	21.4	21.4	22.2	19.6	22.9	21.4	18.7	23.9	21.3	22.8	22.4		
	ESR2013	13.3	16.3	16.8	16.6	18.2	19.5	19.3	19.9	17.6	19.9	21.9	21.9	22.7	19.8	23.2	21.5	18.9	24.0	21.5	23.0	22.6	2.0 (1.4; 2.5)	2004-2024
																							3.5 (2.2; 4.8)	2004-2014
																							0.4 (-0.8; 1.7)	2015-2024
75+	**N**	131	136	144	145	181	189	198	202	195	213	225	211	220	216	251	211	272	252	285	269	286		
	CR	25.2	25.6	26.4	26.0	31.8	32.7	33.7	34.0	32.5	35.2	36.9	34.2	35.7	35.3	41.1	34.4	43.8	40.7	45.0	41.7	43.4		
	ESR2013	25.2	25.3	26.0	25.6	32.3	32.3	33.2	34.1	31.7	35.7	36.3	33.5	35.3	35.0	41.2	35.2	43.7	41.4	45.2	41.4	44.2	2.8 (2.3; 3.3)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Cancer of the biliary system prevalence: by region

3.1.1. Cancer of the biliary system prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	799	2,148	2,883	3,239	3,411	404	1,069	1,433	1,645	1,772
	CR	13.7	36.8	49.5	56	59	6.7	17.8	23.9	27	30
	ESR2013	14.1	38.0	51.0	57.4	60.5	6.2	16.4	22.0	25.2	27.0
Brussels	**N**	61	184	242	280	298	33	91	128	147	156
	CR	9.9	29.9	39.3	45.5	48.4	5.2	14.2	20.0	23.0	24.4
	ESR2013	15.7	45.2	59.3	69.1	73.9	6.5	17.6	25.2	29.0	30.6
Flanders	**N**	435	1,157	1,560	1,741	1,842	230	591	792	911	991
	CR	12.8	34.0	45.9	51.2	54.2	6.6	17.1	22.9	26.3	28.6
	ESR2013	12.3	32.8	44.3	49.4	52.3	5.8	15.0	20.0	23.0	24.9
Wallonia	**N**	303	807	1,081	1,218	1,271	141	387	513	587	625
	CR	16.7	44.5	59.6	67.1	70.0	7.5	20.5	27.1	31.1	33.1
	ESR2013	17.7	46.7	62.5	70.7	73.8	6.9	18.8	24.9	28.4	30.2

4.1. Cancer of the biliary system survival: by region

4.1.1. Cancer of the biliary system survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024				
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All ages 15+**	15,578	52.5% (51.7%; 53.3%)	30.9% (30.1%; 31.7%)	23.0% (22.2%; 23.9%)	16.5% (15.2%; 17.9%)
Males						
Belgium	**All ages 15+**	10,263	53.8% (52.8%; 54.8%)	32.3% (31.3%; 33.3%)	24.0% (22.9%; 25.1%)	15.9% (14.2%; 17.7%)
	15-59	1,606	61.4% (59.0%; 63.8%)	39.9% (37.5%; 42.5%)	31.8% (29.4%; 34.4%)	25.2% (22.4%; 28.4%)
	60-74	5,237	56.9% (55.5%; 58.3%)	35.2% (33.8%; 36.6%)	27.0% (25.6%; 28.5%)	18.8% (16.8%; 20.9%)
	75+	3,421	45.4% (43.7%; 47.2%)	24.1% (22.4%; 25.9%)	15.4% (13.6%; 17.5%)	5.2% (2.6%; 10.3%)
Brussels	**All ages 15+**	859	57.5% (54.1%; 61.1%)	35.3% (31.9%; 39.1%)	24.2% (20.6%; 28.4%)	13.6% (8.4%; 21.8%)
	15-59	202	64.3% (58.0%; 71.3%)	39.8% (33.3%; 47.5%)	31.2% (24.6%; 39.6%)	21.9% (14.3%; 33.7%)
	60-74	395	60.2% (55.4%; 65.4%)	37.7% (32.8%; 43.4%)	26.1% (21.3%; 32.1%)	17.2% (11.0%; 26.7%)
	75+	262	48.3% (42.2%; 55.3%)	28.3% (22.3%; 35.9%)	15.6% (9.7%; 25.1%)	FU<10y
Flanders	**All ages 15+**	5,407	53.6% (52.2%; 55.0%)	32.0% (30.6%; 33.4%)	23.7% (22.3%; 25.2%)	16.9% (14.8%; 19.4%)
	15-59	745	62.7% (59.3%; 66.3%)	40.7% (37.2%; 44.5%)	32.4% (29.0%; 36.3%)	25.3% (21.3%; 30.1%)
	60-74	2,663	57.7% (55.9%; 59.7%)	36.0% (34.1%; 38.0%)	27.9% (25.9%; 29.9%)	20.9% (18.3%; 23.9%)
	75+	1,999	44.7% (42.4%; 47.1%)	23.3% (21.2%; 25.7%)	14.6% (12.4%; 17.1%)	7.3% (3.8%; 14.0%)
Wallonia	**All ages 15+**	3,997	53.2% (51.6%; 54.8%)	32.0% (30.4%; 33.7%)	24.3% (22.6%; 26.1%)	14.8% (12.2%; 18.0%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	15-59	659	58.9% (55.2%; 62.8%)	39.1% (35.4%; 43.1%)	31.1% (27.4%; 35.2%)	25.9% (21.8%; 30.8%)
	60-74	2,179	55.2% (53.1%; 57.4%)	33.7% (31.6%; 36.0%)	26.1% (23.9%; 28.4%)	16.5% (13.5%; 20.0%)
	75+	1,160	46.0% (43.0%; 49.2%)	24.5% (21.5%; 27.8%)	16.7% (13.4%; 20.6%)	3.7% (1.2%; 11.6%)
Females						
Belgium	**All ages 15+**	5,315	50.1% (48.7%; 51.5%)	28.2% (26.9%; 29.6%)	21.2% (19.8%; 22.6%)	17.4% (15.4%; 19.7%)
	15-59	786	66.3% (63.0%; 69.7%)	42.5% (39.1%; 46.2%)	32.1% (28.7%; 35.8%)	28.0% (24.4%; 32.1%)
	60-74	2,067	57.5% (55.4%; 59.7%)	32.2% (30.2%; 34.4%)	24.3% (22.2%; 26.5%)	19.2% (16.8%; 21.9%)
	75+	2,462	38.8% (36.8%; 40.9%)	20.3% (18.5%; 22.2%)	15.1% (13.2%; 17.3%)	12.3% (8.7%; 17.5%)
Brussels	**All ages 15+**	488	52.9% (48.5%; 57.7%)	28.6% (24.5%; 33.4%)	21.7% (17.7%; 26.7%)	16.4% (11.6%; 23.0%)
	15-59	82	68.6% (59.1%; 79.6%)	40.7% (31.0%; 53.4%)	24.9% (16.5%; 37.5%)	23.0% (14.6%; 36.3%)
	60-74	180	61.7% (54.9%; 69.4%)	37.2% (30.4%; 45.4%)	28.0% (21.4%; 36.5%)	21.7% (14.8%; 31.9%)
	75+	226	40.4% (34.2%; 47.7%)	17.3% (12.4%; 24.3%)	15.3% (10.1%; 23.2%)	FU<10y
Flanders	**All ages 15+**	2,997	49.0% (47.2%; 50.9%)	27.0% (25.3%; 28.8%)	20.4% (18.7%; 22.3%)	17.7% (15.4%; 20.4%)
	15-59	424	66.3% (61.9%; 70.9%)	44.4% (39.8%; 49.6%)	34.9% (30.3%; 40.1%)	29.2% (24.4%; 34.9%)
	60-74	1,120	56.0% (53.1%; 59.0%)	29.3% (26.6%; 32.3%)	21.7% (19.1%; 24.6%)	17.1% (14.2%; 20.6%)
	75+	1,453	38.5% (36.0%; 41.3%)	20.2% (17.9%; 22.7%)	15.2% (12.8%; 18.0%)	15.2% (10.9%; 21.1%)
Wallonia	**All ages 15+**	1,830	51.2% (48.9%; 53.6%)	30.0% (27.8%; 32.4%)	22.2% (19.9%; 24.8%)	17.1% (13.1%; 22.3%)
	15-59	280	65.6% (60.2%; 71.4%)	40.1% (34.5%; 46.5%)	29.9% (24.6%; 36.4%)	29.1% (23.6%; 35.9%)
	60-74	767	58.7% (55.3%; 62.3%)	35.3% (31.9%; 39.1%)	27.2% (23.8%; 31.1%)	21.7% (17.7%; 26.7%)
	75+	783	38.8% (35.3%; 42.6%)	21.2% (18.0%; 24.8%)	14.8% (11.6%; 18.8%)	7.8% (3.1%; 19.4%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2. Cancer of the biliary system survival: by tumour type

4.2.1. Cancer of the biliary system survival by type and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
Type	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	15,578	52.5% (51.7%; 53.3%)	38.2% (37.4%; 39.0%)	30.9% (30.1%; 31.7%)	26.3% (25.5%; 27.1%)	23.0% (22.2%; 23.9%)	16.5% (15.2%; 17.9%)
Males							
Cholangiocarcinoma	2,216	44.9% (42.9%; 47.1%)	27.7% (25.8%; 29.8%)	19.6% (17.8%; 21.5%)	14.9% (13.2%; 16.8%)	12.7% (11.0%; 14.6%)	6.9% (4.9%; 9.8%)
Hepatocellular carcinoma	5,930	58.2% (56.9%; 59.5%)	45.0% (43.6%; 46.3%)	37.5% (36.2%; 38.9%)	32.5% (31.2%; 34.0%)	27.8% (26.4%; 29.4%)	17.7% (15.5%; 20.2%)
Adenocarcinoma	1,485	57.9% (55.3%; 60.6%)	43.4% (40.7%; 46.2%)	34.4% (31.8%; 37.3%)	30.3% (27.6%; 33.2%)	27.9% (25.2%; 30.9%)	22.5% (18.4%; 27.6%)
Other and unspecified	651	34.1% (30.5%; 38.1%)	24.2% (20.9%; 28.1%)	21.9% (18.5%; 25.8%)	18.1% (14.8%; 22.3%)	16.8% (13.3%; 21.3%)	11.0% (5.6%; 21.8%)
Females							
Cholangiocarcinoma	1,716	47.2% (44.8%; 49.6%)	28.3% (26.2%; 30.6%)	19.7% (17.8%; 21.9%)	15.0% (13.1%; 17.0%)	12.3% (10.5%; 14.4%)	9.2% (7.0%; 12.1%)
Hepatocellular carcinoma	1,567	57.9% (55.4%; 60.5%)	45.0% (42.4%; 47.6%)	38.4% (35.8%; 41.1%)	32.2% (29.7%; 35.0%)	29.6% (27.0%; 32.5%)	23.1% (19.8%; 27.0%)
Adenocarcinoma	1,410	54.8% (52.2%; 57.6%)	39.6% (37.0%; 42.5%)	32.1% (29.5%; 35.0%)	28.6% (26.0%; 31.6%)	25.5% (22.8%; 28.6%)	23.0% (18.2%; 29.0%)
Other and unspecified	631	28.7% (25.3%; 32.7%)	20.4% (17.2%; 24.1%)	16.9% (13.9%; 20.6%)	15.3% (12.3%; 19.0%)	14.0% (10.8%; 18.0%)	11.7% (6.7%; 20.3%)

4.3. Cancer of the biliary system survival: by tumour location and tumour type and tumour stage

4.3.1. Cancer of the biliary system survival by location, type, stage and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total		15,578	52.5% (51.7%; 53.3%)	38.2% (37.4%; 39.0%)	30.9% (30.1%; 31.7%)	26.3% (25.5%; 27.1%)	23.0% (22.2%; 23.9%)	16.5% (15.2%; 17.9%)
Males								
Hepatic Cholangiocarcinoma	All	1,494	41.7% (39.2%; 44.3%)	24.2% (22.0%; 26.6%)	16.7% (14.7%; 19.0%)	12.1% (10.3%; 14.3%)	10.0% (8.2%; 12.1%)	6.9% (4.9%; 9.7%)
	I	174	78.0% (71.7%; 85.0%)	60.1% (52.7%; 68.6%)	51.4% (43.5%; 60.8%)	46.4% (38.0%; 56.7%)	38.3% (29.7%; 49.5%)	31.3% (22.0%; 44.4%)
	II	182	58.6% (51.7%; 66.5%)	38.0% (31.3%; 46.3%)	33.0% (26.3%; 41.4%)	24.9% (18.4%; 33.7%)	18.7% (12.5%; 27.9%)	FU<10y
	III	171	44.2% (37.2%; 52.5%)	26.4% (20.2%; 34.5%)	15.0% (10.1%; 22.3%)	10.5% (6.0%; 18.2%)	8.4% (4.1%; 16.9%)	FU<10y
	IV	802	30.5% (27.4%; 33.9%)	13.3% (11.0%; 16.0%)	6.0% (4.4%; 8.2%)	2.6% (1.5%; 4.4%)	2.2% (1.2%; 3.9%)	FU<10y
	X/NA	165	36.2% (29.4%; 44.5%)	21.6% (15.9%; 29.2%)	14.7% (9.9%; 21.9%)	9.3% (5.6%; 15.6%)	8.6% (5.0%; 14.7%)	8.0% (4.3%; 15.1%)
Cholangiocarcinoma of gallbladder & biliary tract	All	723	51.7% (48.0%; 55.6%)	34.9% (31.4%; 38.8%)	25.4% (22.0%; 29.2%)	20.6% (17.4%; 24.5%)	18.2% (15.0%; 22.2%)	7.7% (4.2%; 14.1%)
Hepatocellular carcinoma	All	5,930	58.2% (56.9%; 59.5%)	45.0% (43.6%; 46.3%)	37.5% (36.2%; 38.9%)	32.5% (31.2%; 34.0%)	27.8% (26.4%; 29.4%)	17.7% (15.5%; 20.2%)
	I	1,335	86.2% (84.1%; 88.3%)	75.3% (72.6%; 78.0%)	66.5% (63.5%; 69.7%)	60.4% (57.0%; 63.9%)	52.3% (48.5%; 56.4%)	34.9% (28.3%; 43.2%)
	II	1,201	74.2% (71.6%; 76.8%)	59.1% (56.1%; 62.2%)	48.8% (45.7%; 52.2%)	41.8% (38.5%; 45.3%)	38.7% (35.3%; 42.5%)	28.3% (23.5%; 33.9%)
	III	1,056	42.0% (39.0%; 45.2%)	28.3% (25.5%; 31.3%)	22.0% (19.3%; 25.0%)	18.3% (15.6%; 21.3%)	14.5% (11.9%; 17.6%)	4.8% (1.8%; 13.2%)
	IV	1,073	24.2% (21.7%; 26.9%)	12.2% (10.3%; 14.4%)	8.2% (6.6%; 10.2%)	5.7% (4.2%; 7.6%)	4.5% (3.1%; 6.4%)	FU<10y
	X/NA	1,265	55.8% (53.1%; 58.7%)	41.3% (38.5%; 44.3%)	34.0% (31.3%; 37.0%)	29.1% (26.4%; 32.1%)	23.3% (20.6%; 26.3%)	14.6% (11.9%; 18.1%)
Adenocarcinoma of gallbladder & biliary tract	All	1,312	59.1% (56.4%; 62.0%)	44.2% (41.4%; 47.2%)	35.0% (32.2%; 38.1%)	31.2% (28.3%; 34.3%)	29.2% (26.3%; 32.5%)	24.2% (19.6%; 29.8%)
	I	179	88.6% (83.1%; 94.4%)	79.8% (72.7%; 87.7%)	70.6% (62.3%; 80.1%)	68.1% (59.1%; 78.4%)	65.5% (55.8%; 76.9%)	68.7% (55.0%; 85.9%)
	II	161	83.2% (76.9%; 90.0%)	76.6% (69.1%; 84.9%)	63.8% (55.0%; 74.0%)	56.7% (47.4%; 67.9%)	52.7% (42.7%; 65.1%)	46.3% (31.2%; 68.9%)
	III	264	79.0% (73.9%; 84.5%)	63.6% (57.6%; 70.3%)	51.1% (44.6%; 58.5%)	44.9% (38.3%; 52.6%)	41.9% (35.2%; 50.0%)	26.8% (14.5%; 49.5%)
	IV	213	35.7% (29.7%; 42.9%)	14.2% (10.1%; 20.0%)	6.1% (3.5%; 10.7%)	6.3% (3.6%; 10.9%)	6.3% (3.6%; 10.9%)	6.1% (3.0%; 12.4%)

Net Survival Probability, 2015-2024																				
Type	**Stage**	**N at risk**	**1-y**	**(95%CI)**		**2-y**	**(95%CI)**		**3-y**	**(95%CI)**		**4-y**	**(95%CI)**		**5-y**	**(95%CI)**		**10-y**	**(95%CI)**	
	X/NA	498	39.9%	(35.7%;	44.6%)	23.3%	(19.7%;	27.7%)	16.6%	(13.3%;	20.6%)	13.4%	(10.4%;	17.3%)	12.1%	(9.2%;	16.1%)	8.2%	(4.9%;	13.7%)
Other and unspecified	All	824	37.1%	(33.8%;	40.7%)	27.0%	(23.9%;	30.5%)	23.6%	(20.6%;	27.1%)	19.2%	(16.2%;	22.9%)	17.1%	(14.0%;	20.9%)	11.3%	(6.6%;	19.4%)
	I	70	75.9%	(65.7%;	87.8%)	68.0%	(56.4%;	81.8%)	62.7%	(50.3%;	78.1%)	49.7%	(35.5%;	69.6%)	42.0%	(28.3%;	62.4%)	FU<10y		
	II	62	56.9%	(45.4%;	71.4%)	44.7%	(33.3%;	60.0%)	33.1%	(22.6%;	48.6%)	27.8%	(17.5%;	44.0%)	26.6%	(16.4%;	43.4%)	17.5%	(5.8%;	53.0%)
	III	89	39.0%	(29.9%;	51.0%)	30.2%	(21.5%;	42.3%)	22.3%	(14.4%;	34.6%)	18.8%	(10.9%;	32.2%)	15.9%	(7.8%;	32.4%)	FU<10y		
	IV	204	20.2%	(15.4%;	26.7%)	11.0%	(7.4%;	16.4%)	10.4%	(6.8%;	15.9%)	8.5%	(5.2%;	13.9%)	3.9%	(1.5%;	10.2%)	FU<10y		
	X/NA	399	35.4%	(30.8%;	40.6%)	24.6%	(20.4%;	29.6%)	21.9%	(17.7%;	26.9%)	18.0%	(13.9%;	23.2%)	17.1%	(13.0%;	22.5%)	11.5%	(6.6%;	20.1%)
Females																				
Hepatic Cholangiocarcinoma	All	1,211	48.0%	(45.2%;	51.0%)	29.0%	(26.4%;	31.8%)	20.2%	(17.8%;	22.8%)	15.4%	(13.2%;	17.9%)	12.4%	(10.3%;	15.0%)	8.3%	(6.0%;	11.5%)
	I	124	82.8%	(75.9%;	90.3%)	66.1%	(57.4%;	76.0%)	59.5%	(50.4%;	70.2%)	50.2%	(40.8%;	61.9%)	44.3%	(34.3%;	57.1%)	26.9%	(14.5%;	49.8%)
	II	134	72.5%	(65.0%;	80.8%)	51.0%	(42.8%;	60.8%)	45.2%	(36.9%;	55.3%)	40.2%	(31.7%;	50.9%)	30.2%	(21.5%;	42.6%)	17.2%	(8.6%;	34.2%)
	III	149	51.1%	(43.5%;	60.1%)	31.4%	(24.4%;	40.5%)	20.4%	(14.3%;	29.1%)	18.0%	(12.2%;	26.6%)	16.9%	(11.1%;	25.8%)	11.0%	(5.5%;	21.7%)
	IV	675	37.9%	(34.3%;	41.8%)	17.8%	(15.0%;	21.0%)	8.1%	(6.1%;	10.6%)	4.2%	(2.8%;	6.4%)	2.8%	(1.6%;	4.9%)	FU<10y		
	X/NA	129	38.3%	(30.6%;	47.9%)	26.4%	(19.5%;	35.7%)	18.7%	(12.7%;	27.5%)	11.2%	(6.6%;	19.2%)	8.2%	(4.3%;	15.7%)	8.5%	(3.7%;	19.6%)
Cholangiocarcinoma of gallbladder & biliary tract	All	507	45.1%	(40.9%;	49.8%)	26.7%	(23.0%;	31.1%)	18.8%	(15.4%;	22.9%)	14.1%	(11.0%;	18.1%)	12.2%	(9.2%;	16.3%)	11.2%	(7.3%;	17.0%)
Hepatocellular carcinoma	All	1,567	57.9%	(55.4%;	60.5%)	45.0%	(42.4%;	47.6%)	38.4%	(35.8%;	41.1%)	32.2%	(29.7%;	35.0%)	29.6%	(27.0%;	32.5%)	23.1%	(19.8%;	27.0%)
	I	401	83.8%	(80.0%;	87.8%)	73.2%	(68.6%;	78.2%)	65.5%	(60.3%;	71.2%)	58.9%	(53.2%;	65.1%)	55.2%	(49.3%;	61.9%)	44.1%	(34.5%;	56.5%)
	II	277	75.3%	(70.1%;	80.8%)	61.8%	(55.9%;	68.3%)	53.5%	(47.3%;	60.6%)	43.9%	(37.4%;	51.7%)	37.0%	(30.2%;	45.4%)	25.0%	(17.5%;	35.6%)
	III	275	37.7%	(32.3%;	44.0%)	25.3%	(20.5%;	31.3%)	19.9%	(15.4%;	25.6%)	15.2%	(11.1%;	20.8%)	15.0%	(10.9%;	20.6%)	8.8%	(4.4%;	17.8%)
	IV	267	26.2%	(21.3%;	32.1%)	12.1%	(8.6%;	16.9%)	8.7%	(5.8%;	13.1%)	5.2%	(2.9%;	9.4%)	3.8%	(1.8%;	8.0%)	FU<10y		
	X/NA	347	54.4%	(49.3%;	60.1%)	40.0%	(34.9%;	45.8%)	33.1%	(28.2%;	38.8%)	26.9%	(22.3%;	32.6%)	25.6%	(20.8%;	31.4%)	21.5%	(16.4%;	28.0%)
Adenocarcinoma of gallbladder & biliary tract	All	1,324	55.0%	(52.3%;	57.9%)	39.6%	(36.9%;	42.5%)	32.1%	(29.4%;	35.0%)	28.7%	(26.0%;	31.8%)	25.6%	(22.8%;	28.9%)	23.5%	(18.3%;	30.1%)
	I	145	88.7%	(82.9%;	94.8%)	81.6%	(74.2%;	89.8%)	75.5%	(66.9%;	85.2%)	74.6%	(65.3%;	85.1%)	67.2%	(56.5%;	80.0%)	51.5%	(30.9%;	86.0%)
	II	203	85.4%	(80.1%;	90.9%)	70.1%	(63.4%;	77.6%)	61.1%	(53.6%;	69.8%)	58.7%	(50.7%;	68.0%)	59.0%	(50.3%;	69.2%)	52.9%	(37.7%;	74.3%)

Net Survival Probability, 2015-2024																				
Type	**Stage**	**N at risk**	**1-y**	**(95%CI)**		**2-y**	**(95%CI)**		**3-y**	**(95%CI)**		**4-y**	**(95%CI)**		**5-y**	**(95%CI)**		**10-y**	**(95%CI)**	
	III	277	66.1%	(60.6%;	72.2%)	49.2%	(43.2%;	56.0%)	37.1%	(31.2%;	44.1%)	29.5%	(23.7%;	36.8%)	24.3%	(18.4%;	32.0%)	26.4%	(17.0%;	41.1%)
	IV	307	32.5%	(27.6%;	38.3%)	14.4%	(10.8%;	19.0%)	10.1%	(7.1%;	14.4%)	8.0%	(5.2%;	12.3%)	6.1%	(3.6%;	10.4%)	6.6%	(3.9%;	11.2%)
	X/NA	392	36.5%	(31.9%;	41.8%)	20.9%	(17.1%;	25.7%)	14.4%	(11.0%;	18.7%)	11.7%	(8.5%;	16.1%)	9.5%	(6.5%;	13.8%)	9.4%	(6.2%;	14.5%)
Other and unspecified	All	715	31.4%	(28.1%;	35.2%)	22.7%	(19.6%;	26.2%)	18.8%	(15.9%;	22.3%)	16.6%	(13.7%;	20.2%)	15.1%	(12.1%;	18.8%)	12.2%	(7.8%;	19.1%)
	I	45	N<50			N<50			N<50			N<50			N<50			N<50		
	II	55	57.1%	(44.9%;	72.7%)	50.2%	(37.7%;	66.9%)	44.9%	(32.2%;	62.7%)	40.0%	(26.9%;	59.5%)	33.5%	(20.1%;	55.9%)	FU<10y		
	III	67	32.0%	(22.4%;	45.6%)	19.7%	(12.0%;	32.2%)	18.2%	(10.8%;	30.8%)	16.5%	(9.4%;	29.0%)	17.3%	(9.8%;	30.4%)	FU<10y		
	IV	210	18.0%	(13.5%;	24.2%)	8.1%	(5.1%;	12.9%)	6.6%	(3.9%;	11.1%)	5.2%	(2.9%;	9.5%)	5.3%	(2.9%;	9.6%)	4.3%	(2.0%;	9.0%)
	X/NA	338	29.8%	(25.1%;	35.4%)	20.9%	(16.7%;	26.2%)	17.6%	(13.5%;	22.8%)	15.7%	(11.7%;	21.1%)	13.9%	(9.8%;	19.7%)	12.1%	(5.8%;	25.4%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Cancer of the biliary system survival trends: by tumour type

5.1.1. Cancer of the biliary system survival trends by type and sex: number at risk and net survival probabilities, 2004-2024

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Type	Period	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Total	**2004-2009**	3,038	49.1% (47.3%; 51.0%)	27.4% (25.8%; 29.2%)	20.7% (19.1%; 22.4%)	2,053	46.5% (44.3%; 48.8%)	25.0% (23.1%; 27.2%)	19.6% (17.7%; 21.6%)
	2010-2014	3,776	51.6% (49.9%; 53.3%)	29.1% (27.6%; 30.7%)	21.9% (20.4%; 23.4%)	2,214	48.0% (45.9%; 50.2%)	26.5% (24.6%; 28.6%)	19.5% (17.7%; 21.5%)
	2015-2019	4,799	52.9% (51.5%; 54.4%)	31.4% (30.0%; 32.9%)	23.2% (21.8%; 24.6%)	2,455	49.6% (47.6%; 51.6%)	27.4% (25.6%; 29.4%)	20.9% (19.2%; 22.8%)
	2020-2024	5,467	54.5% (53.2%; 55.9%)	33.0% (31.5%; 34.4%)	25.0% (23.4%; 26.8%)	2,860	50.6% (48.7%; 52.5%)	29.0% (27.2%; 31.0%)	21.1% (19.1%; 23.4%)
Cholangiocarcinoma	**2004-2009**	566	44.1% (40.1%; 48.5%)	18.3% (15.2%; 22.0%)	12.0% (9.4%; 15.3%)	490	41.4% (37.2%; 46.1%)	16.7% (13.6%; 20.4%)	10.2% (7.7%; 13.5%)
	2010-2014	685	47.8% (44.1%; 51.9%)	19.9% (17.0%; 23.4%)	11.7% (9.3%; 14.7%)	538	44.8% (40.8%; 49.3%)	19.1% (15.9%; 22.9%)	9.9% (7.5%; 12.9%)
	2015-2019	869	45.6% (42.3%; 49.1%)	20.8% (18.1%; 23.8%)	13.2% (10.9%; 15.9%)	668	49.4% (45.7%; 53.5%)	20.5% (17.5%; 24.0%)	13.0% (10.5%; 16.1%)
	2020-2024	1,347	44.5% (41.9%; 47.3%)	18.7% (16.4%; 21.3%)	12.8% (10.3%; 15.9%)	1,048	45.7% (42.7%; 48.9%)	19.2% (16.7%; 22.1%)	11.4% (8.8%; 14.8%)
Hepatocellular carcinoma	**2004-2009**	1,615	50.2% (47.7%; 52.8%)	30.0% (27.7%; 32.5%)	22.6% (20.4%; 25.0%)	560	52.4% (48.3%; 56.8%)	32.7% (28.8%; 37.1%)	25.0% (21.3%; 29.2%)
	2010-2014	2,208	53.5% (51.4%; 55.7%)	31.8% (29.8%; 34.0%)	24.2% (22.2%; 26.3%)	682	54.2% (50.5%; 58.2%)	35.8% (32.2%; 39.9%)	26.4% (22.9%; 30.4%)
	2015-2019	2,811	56.1% (54.2%; 58.0%)	35.5% (33.6%; 37.4%)	26.1% (24.3%; 28.0%)	751	55.6% (52.1%; 59.4%)	37.1% (33.6%; 41.0%)	29.7% (26.3%; 33.6%)
	2020-2024	3,119	60.1% (58.3%; 61.9%)	39.3% (37.4%; 41.4%)	29.9% (27.6%; 32.5%)	816	59.9% (56.6%; 63.5%)	39.7% (36.1%; 43.7%)	28.7% (24.6%; 33.4%)

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Type	Period	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Adenocarcinoma	**2004-2009**	665	54.6% (50.7%; 58.7%)	30.1% (26.5%; 34.2%)	23.3% (19.8%; 27.3%)	788	48.9% (45.4%; 52.7%)	26.9% (23.6%; 30.6%)	23.2% (20.0%; 26.9%)
	2010-2014	620	56.6% (52.7%; 60.9%)	34.6% (30.7%; 39.0%)	27.6% (23.8%; 32.1%)	694	51.0% (47.3%; 55.0%)	26.5% (23.2%; 30.3%)	21.9% (18.6%; 25.8%)
	2015-2019	786	57.6% (54.1%; 61.4%)	32.3% (28.9%; 36.1%)	26.2% (22.9%; 30.0%)	717	52.5% (48.8%; 56.4%)	28.4% (25.0%; 32.2%)	22.0% (18.7%; 25.8%)
	2020-2024	699	58.1% (54.4%; 62.1%)	37.0% (33.0%; 41.5%)	29.4% (24.8%; 34.8%)	693	57.3% (53.6%; 61.2%)	36.7% (32.8%; 41.0%)	30.2% (25.6%; 35.6%)
Other and unspecified	**2004-2009**	193	36.0% (29.6%; 43.7%)	22.8% (17.2%; 30.3%)	21.8% (16.1%; 29.6%)	215	34.0% (28.0%; 41.2%)	17.3% (12.7%; 23.7%)	13.0% (8.5%; 19.8%)
	2010-2014	270	35.1% (29.6%; 41.5%)	18.2% (13.7%; 24.1%)	15.4% (11.1%; 21.5%)	300	32.2% (27.2%; 38.2%)	18.7% (14.3%; 24.4%)	15.5% (11.2%; 21.5%)
	2015-2019	339	34.1% (29.2%; 39.9%)	22.4% (17.9%; 28.0%)	17.1% (12.6%; 23.2%)	324	29.8% (25.1%; 35.5%)	17.2% (13.2%; 22.5%)	13.8% (9.9%; 19.3%)
	2020-2024	312	34.0% (29.0%; 40.0%)	20.6% (16.1%; 26.5%)	17.0% (12.1%; 23.8%)	307	27.6% (22.8%; 33.3%)	16.6% (12.4%; 22.1%)	13.4% (9.0%; 19.8%)

5.2. Cancer of the biliary system survival trends: by tumour location and tumour type and tumour stage

5.2.1. Cancer of the biliary system survival trends by location, type, stage and sex: number at risk and net survival probabilities, 2004-2024

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Location	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Hepatic Cholangiocarcinoma	**2004-2009**	All	315	40.6% (35.5%; 46.6%)	17.3% (13.4%; 22.3%)	10.4% (7.3%; 14.7%)	271	43.2% (37.6%; 49.6%)	19.8% (15.5%; 25.4%)	12.2% (8.7%; 17.1%)
		I	21	N<50	N<50	N<50	14	N<50	N<50	N<50
		II	19	N<50	N<50	N<50	15	N<50	N<50	N<50
		III	70	51.7% (41.0%; 65.1%)	19.6% (11.9%; 32.2%)	9.6% (4.6%; 20.1%)	74	57.6% (47.3%; 70.2%)	26.8% (18.2%; 39.3%)	19.9% (12.2%; 32.2%)
		IV	72	25.6% (17.3%; 38.0%)	4.4% (1.5%; 12.6%)	1.6% (0.3%; 7.5%)	74	32.8% (23.7%; 45.4%)	11.0% (5.8%; 20.7%)	4.1% (1.5%; 11.6%)
		X/NA	133	28.3% (21.5%; 37.2%)	12.2% (7.6%; 19.7%)	5.2% (2.5%; 11.1%)	94	29.5% (21.6%; 40.4%)	12.2% (7.0%; 21.4%)	3.8% (1.4%; 10.5%)
	2010-2014	All	403	42.0% (37.4%; 47.2%)	17.1% (13.6%; 21.4%)	10.4% (7.7%; 14.2%)	347	44.9% (39.9%; 50.5%)	20.4% (16.5%; 25.3%)	9.7% (6.9%; 13.6%)
		I	29	N<50	N<50	N<50	20	N<50	N<50	N<50
		II	41	N<50	N<50	N<50	39	N<50	N<50	N<50
		III	16	N<50	N<50	N<50	18	N<50	N<50	N<50
		IV	194	36.5% (30.3%; 44.1%)	8.4% (5.2%; 13.5%)	5.9% (3.3%; 10.5%)	163	36.7% (30.0%; 45.0%)	14.5% (9.9%; 21.2%)	6.0% (3.2%; 11.0%)
		X/NA	123	24.3% (17.7%; 33.3%)	7.3% (3.8%; 14.1%)	3.3% (1.2%; 9.2%)	107	36.5% (28.3%; 47.1%)	10.6% (6.0%; 18.9%)	3.7% (1.4%; 10.0%)
	2015-2019	All	580	42.6% (38.7%; 46.9%)	18.1% (15.0%; 21.7%)	9.8% (7.5%; 12.8%)	484	50.1% (45.8%; 54.9%)	21.0% (17.6%; 25.2%)	13.2% (10.3%; 16.9%)
		I	62	84.2% (74.8%; 94.8%)	63.1% (51.2%; 77.8%)	46.2% (34.2%; 62.3%)	43	N<50	N<50	N<50
		II	60	58.1% (46.7%; 72.3%)	31.5% (21.3%; 46.5%)	12.9% (6.3%; 26.6%)	53	69.0% (57.4%; 82.8%)	40.3% (28.8%; 56.5%)	28.6% (17.7%; 46.0%)
		III	59	48.9% (37.5%; 63.7%)	9.5% (4.2%; 21.5%)	3.7% (1.0%; 13.2%)	52	59.1% (46.9%; 74.6%)	29.6% (19.0%; 46.3%)	24.0% (14.1%; 40.8%)
		IV	285	30.0% (25.0%; 35.9%)	8.2% (5.5%; 12.3%)	2.7% (1.3%; 5.5%)	246	42.0% (36.2%; 48.8%)	9.2% (6.2%; 13.7%)	3.1% (1.5%; 6.2%)
		X/NA	114	39.7% (31.5%; 49.9%)	14.9% (9.4%; 23.7%)	8.7% (4.7%; 16.1%)	90	37.5% (28.6%; 49.2%)	18.6% (11.8%; 29.1%)	8.2% (4.0%; 16.8%)
	2020-2024	All	914	41.1% (37.9%; 44.5%)	15.8% (13.3%; 18.8%)	11.5% (8.8%; 15.0%)	727	46.6% (43.0%; 50.5%)	19.4% (16.4%; 22.9%)	11.6% (8.6%; 15.7%)
		I	112	74.6% (66.5%; 83.7%)	43.1% (33.2%; 55.9%)	36.9% (24.7%; 55.1%)	81	79.9% (71.1%; 89.8%)	59.5% (48.2%; 73.5%)	41.5% (28.7%; 60.1%)

Location	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	122	58.8% (50.4%; 68.6%)	34.0% (25.8%; 44.8%)	25.8% (17.5%; 38.1%)	81	74.7% (65.3%; 85.4%)	48.6% (37.8%; 62.3%)	30.2% (18.2%; 50.3%)
		III	112	41.6% (33.3%; 52.1%)	18.8% (12.3%; 28.9%)	11.7% (5.1%; 26.9%)	97	46.9% (37.7%; 58.2%)	14.8% (8.5%; 25.8%)	FU<5y
		IV	517	30.7% (26.9%; 35.0%)	4.3% (2.6%; 7.0%)	2.1% (0.9%; 4.9%)	429	35.5% (31.2%; 40.4%)	7.1% (4.7%; 10.5%)	2.6% (1.1%; 6.5%)
		X/NA	51	28.1% (18.1%; 43.7%)	15.5% (8.0%; 30.1%)	9.3% (3.6%; 23.9%)	39	N<50	N<50	N<50
Cholangiocarcinoma of gallbladder & biliary tract	**2004-2009**	All	252	48.7% (42.7%; 55.5%)	19.5% (14.9%; 25.3%)	13.9% (10.0%; 19.4%)	219	39.3% (33.2%; 46.5%)	12.7% (8.9%; 18.2%)	7.7% (4.8%; 12.5%)
	2010-2014	All	283	56.0% (50.2%; 62.4%)	24.0% (19.2%; 29.9%)	13.5% (9.7%; 18.8%)	191	44.8% (38.1%; 52.6%)	16.6% (12.0%; 23.1%)	10.2% (6.6%; 15.8%)
	2015-2019	All	289	51.6% (46.0%; 57.9%)	26.2% (21.3%; 32.2%)	19.9% (15.5%; 25.7%)	186	47.6% (40.8%; 55.6%)	19.4% (14.3%; 26.4%)	13.2% (8.9%; 19.5%)
	2020-2024	All	434	51.7% (47.1%; 56.8%)	24.8% (20.4%; 30.0%)	15.5% (10.8%; 22.2%)	321	43.7% (38.4%; 49.6%)	18.7% (14.5%; 24.0%)	11.2% (7.1%; 17.8%)
Hepatocellular carcinoma	**2004-2009**	All	1,615	50.2% (47.7%; 52.8%)	30.0% (27.7%; 32.5%)	22.6% (20.4%; 25.0%)	560	52.4% (48.3%; 56.8%)	32.7% (28.8%; 37.1%)	25.0% (21.3%; 29.2%)
		I	157	80.4% (74.0%; 87.3%)	69.1% (61.3%; 77.8%)	60.4% (51.9%; 70.4%)	79	80.4% (71.6%; 90.2%)	58.6% (47.9%; 71.7%)	50.3% (39.3%; 64.2%)
		II	260	75.8% (70.5%; 81.5%)	56.5% (50.4%; 63.5%)	47.0% (40.6%; 54.4%)	85	71.6% (62.5%; 82.1%)	49.9% (39.9%; 62.6%)	42.8% (32.8%; 56.0%)
		III	295	43.3% (37.9%; 49.5%)	17.8% (13.7%; 23.0%)	10.9% (7.6%; 15.6%)	99	45.3% (36.3%; 56.5%)	24.1% (16.7%; 34.8%)	17.0% (10.6%; 27.1%)
		IV	168	17.7% (12.8%; 24.6%)	7.7% (4.5%; 13.2%)	2.7% (1.0%; 6.9%)	62	21.3% (13.3%; 34.1%)	5.0% (1.8%; 13.9%)	3.3% (1.0%; 11.3%)
		X/NA	735	44.8% (41.2%; 48.7%)	22.2% (19.2%; 25.7%)	14.9% (12.3%; 18.1%)	235	47.0% (40.9%; 54.0%)	28.6% (23.1%; 35.5%)	18.6% (13.9%; 24.9%)
	2010-2014	All	2,208	53.5% (51.4%; 55.7%)	31.8% (29.8%; 34.0%)	24.2% (22.2%; 26.3%)	682	54.2% (50.5%; 58.2%)	35.8% (32.2%; 39.9%)	26.4% (22.9%; 30.4%)
		I	308	80.0% (75.3%; 84.9%)	61.0% (55.1%; 67.5%)	52.8% (46.2%; 60.4%)	124	86.5% (80.2%; 93.3%)	62.7% (54.0%; 72.7%)	48.1% (39.2%; 59.1%)
		II	343	71.3% (66.5%; 76.5%)	47.5% (42.1%; 53.6%)	39.7% (34.2%; 46.0%)	121	70.2% (62.3%; 79.2%)	57.7% (48.8%; 68.2%)	41.2% (32.0%; 53.0%)
		III	313	38.2% (33.0%; 44.1%)	18.3% (14.2%; 23.6%)	10.1% (7.0%; 14.8%)	67	35.2% (25.3%; 48.9%)	9.6% (4.5%; 20.5%)	8.1% (3.5%; 18.4%)
		IV	318	24.6% (20.2%; 29.9%)	6.0% (3.8%; 9.4%)	2.0% (0.9%; 4.4%)	95	21.4% (14.6%; 31.5%)	6.5% (3.1%; 13.8%)	4.1% (1.6%; 10.8%)
		X/NA	926	53.1% (49.9%; 56.6%)	29.8% (26.8%; 33.1%)	21.2% (18.5%; 24.4%)	275	48.6% (42.9%; 55.1%)	30.4% (25.2%; 36.8%)	22.0% (17.2%; 28.2%)
	2015-2019	All	2,811	56.1% (54.2%; 58.0%)	35.5% (33.6%; 37.4%)	26.1% (24.3%; 28.0%)	751	55.6% (52.1%; 59.4%)	37.1% (33.6%; 41.0%)	29.7% (26.3%; 33.6%)
		I	519	85.8% (82.6%; 89.2%)	65.7% (61.2%; 70.6%)	52.4% (47.3%; 58.0%)	150	83.0% (76.8%; 89.7%)	69.0% (61.0%; 77.9%)	61.3% (52.8%; 71.2%)
		II	486	72.8% (68.7%; 77.1%)	46.5% (41.9%; 51.7%)	36.1% (31.6%; 41.3%)	117	74.9% (67.1%; 83.7%)	52.0% (43.0%; 63.0%)	36.0% (27.4%; 47.3%)

Location	Period	Stage	Males				Females			
				Net Survival Probability				Net Survival Probability		
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		III	417	37.5% (33.0%; 42.6%)	18.1% (14.5%; 22.5%)	11.9% (8.9%; 16.0%)	109	34.9% (26.9%; 45.3%)	16.4% (10.5%; 25.4%)	12.6% (7.5%; 21.2%)
		IV	439	19.3% (15.8%; 23.4%)	5.2% (3.4%; 7.9%)	2.7% (1.5%; 4.9%)	113	19.1% (13.0%; 28.0%)	6.6% (3.3%; 13.2%)	3.8% (1.4%; 9.8%)
		X/NA	950	56.5% (53.3%; 59.9%)	34.8% (31.6%; 38.3%)	23.6% (20.6%; 26.9%)	262	55.6% (49.8%; 62.2%)	33.9% (28.3%; 40.6%)	26.8% (21.4%; 33.5%)
	2020-2024	All	3,119	60.1% (58.3%; 61.9%)	39.3% (37.4%; 41.4%)	29.9% (27.6%; 32.5%)	816	59.9% (56.6%; 63.5%)	39.7% (36.1%; 43.7%)	28.7% (24.6%; 33.4%)
		I	816	86.4% (83.8%; 89.1%)	66.9% (62.9%; 71.1%)	51.7% (46.0%; 58.1%)	251	84.2% (79.5%; 89.2%)	63.1% (56.2%; 70.7%)	49.4% (41.2%; 59.3%)
		II	715	75.1% (71.8%; 78.6%)	50.4% (46.2%; 55.0%)	41.9% (36.8%; 47.8%)	160	75.5% (68.8%; 82.9%)	54.9% (46.7%; 64.5%)	35.0% (24.5%; 50.2%)
		III	639	45.0% (41.2%; 49.1%)	24.6% (21.0%; 28.8%)	16.1% (12.2%; 21.2%)	166	39.4% (32.5%; 47.8%)	22.3% (16.5%; 30.2%)	16.4% (10.9%; 24.6%)
		IV	634	27.6% (24.2%; 31.4%)	10.2% (7.8%; 13.2%)	5.9% (3.9%; 9.1%)	154	31.4% (24.8%; 39.8%)	10.2% (6.1%; 16.9%)	3.1% (1.0%; 9.3%)
		X/NA	315	53.7% (48.3%; 59.7%)	31.4% (26.2%; 37.7%)	24.2% (18.7%; 31.4%)	85	50.5% (40.8%; 62.6%)	30.6% (21.8%; 43.0%)	20.6% (12.3%; 34.6%)
Adenocarcinoma of gallbladder & biliary tract	**2004-2009**	All	614	54.3% (50.3%; 58.6%)	29.7% (26.0%; 34.0%)	23.8% (20.2%; 28.1%)	741	49.7% (46.1%; 53.6%)	26.8% (23.4%; 30.6%)	22.9% (19.7%; 26.8%)
		I	131	79.9% (72.7%; 87.8%)	64.3% (55.2%; 74.8%)	58.1% (48.1%; 70.2%)	188	75.5% (69.2%; 82.5%)	55.9% (48.2%; 64.8%)	53.2% (44.9%; 63.1%)
		II	149	67.0% (59.5%; 75.4%)	36.0% (28.6%; 45.3%)	27.0% (20.3%; 36.1%)	175	64.3% (57.3%; 72.2%)	30.1% (23.7%; 38.3%)	23.4% (17.4%; 31.4%)
		III	46	N<50	N<50	N<50	45	N<50	N<50	N<50
		IV	89	30.7% (22.4%; 42.2%)	9.7% (4.9%; 19.2%)	5.1% (2.0%; 12.9%)	127	16.0% (10.7%; 23.7%)	1.6% (0.5%; 5.5%)	0.8% (0.2%; 3.9%)
		X/NA	199	35.3% (29.0%; 43.0%)	11.8% (7.7%; 17.9%)	7.9% (4.5%; 13.8%)	206	34.4% (28.2%; 41.9%)	14.4% (9.5%; 21.8%)	10.0% (6.1%; 16.6%)
	2010-2014	All	562	56.9% (52.7%; 61.4%)	35.1% (30.9%; 39.7%)	28.0% (23.9%; 32.7%)	666	49.8% (46.0%; 53.9%)	25.4% (22.1%; 29.3%)	21.1% (17.8%; 25.0%)
		I	73	86.8% (78.4%; 96.0%)	78.9% (67.7%; 92.0%)	74.3% (61.2%; 90.2%)	66	91.7% (84.2%; 99.9%)	81.1% (70.6%; 93.3%)	80.6% (68.3%; 95.1%)
		II	113	83.6% (76.3%; 91.6%)	56.9% (47.4%; 68.4%)	40.6% (30.8%; 53.5%)	119	74.8% (66.9%; 83.7%)	48.5% (39.3%; 59.7%)	37.6% (28.5%; 49.7%)
		III	56	57.1% (45.1%; 72.1%)	28.5% (18.5%; 44.1%)	17.7% (9.7%; 32.4%)	105	55.7% (46.6%; 66.6%)	20.3% (13.5%; 30.4%)	13.8% (8.0%; 23.7%)
		IV	74	26.9% (18.4%; 39.4%)	9.0% (4.3%; 18.9%)	3.3% (1.0%; 11.6%)	128	27.3% (20.5%; 36.3%)	5.2% (2.5%; 10.9%)	2.6% (0.9%; 7.8%)
		X/NA	246	44.4% (38.4%; 51.4%)	21.1% (16.1%; 27.6%)	17.7% (13.0%; 24.1%)	248	35.8% (30.2%; 42.5%)	11.8% (8.2%; 17.0%)	9.0% (5.7%; 14.0%)
	2015-2019	All	692	58.4% (54.6%; 62.4%)	32.4% (28.8%; 36.5%)	27.2% (23.7%; 31.4%)	671	51.5% (47.7%; 55.6%)	27.4% (24.0%; 31.3%)	21.4% (18.0%; 25.3%)
		I	81	94.1% (87.5%; 101.1%)	71.8% (60.3%; 85.5%)	65.4% (52.8%; 81.0%)	65	86.8% (78.3%; 96.4%)	80.7% (69.3%; 94.0%)	76.8% (63.3%; 93.0%)

Location	Period	Stage	Males				Females			
				Net Survival Probability				Net Survival Probability		
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	75	79.7% (70.4%; 90.2%)	58.3% (46.8%; 72.7%)	45.1% (33.7%; 60.2%)	87	81.7% (73.4%; 91.1%)	52.7% (42.2%; 65.8%)	46.0% (35.2%; 60.0%)
		III	128	82.6% (75.7%; 90.0%)	51.2% (42.4%; 61.7%)	45.0% (36.2%; 56.0%)	126	61.4% (53.2%; 70.9%)	30.8% (23.2%; 40.7%)	19.0% (12.6%; 28.5%)
		IV	102	35.4% (27.2%; 46.2%)	4.3% (1.7%; 10.5%)	4.3% (1.7%; 10.5%)	128	34.3% (26.9%; 43.7%)	8.1% (4.5%; 14.6%)	4.9% (2.2%; 10.7%)
		X/NA	309	40.9% (35.6%; 47.1%)	17.0% (13.1%; 22.2%)	12.7% (9.0%; 17.8%)	265	36.4% (30.8%; 42.9%)	13.6% (9.8%; 18.9%)	8.3% (5.2%; 13.4%)
	2020-2024	All	620	59.9% (56.0%; 64.1%)	38.1% (33.8%; 42.9%)	30.7% (25.8%; 36.5%)	653	58.6% (54.8%; 62.7%)	37.5% (33.5%; 42.1%)	31.0% (26.1%; 36.7%)
		I	98	84.1% (76.1%; 92.9%)	70.8% (59.5%; 84.2%)	65.6% (50.7%; 85.0%)	80	89.7% (82.2%; 98.0%)	70.3% (58.2%; 84.9%)	51.2% (35.2%; 74.6%)
		II	86	85.9% (77.9%; 94.8%)	67.5% (54.9%; 83.0%)	59.3% (42.9%; 82.0%)	116	88.1% (81.6%; 95.0%)	68.8% (59.0%; 80.2%)	74.8% (63.3%; 88.4%)
		III	136	75.6% (68.4%; 83.7%)	51.6% (42.7%; 62.4%)	34.8% (24.6%; 49.1%)	151	70.0% (62.8%; 78.1%)	43.9% (35.6%; 54.1%)	31.3% (22.0%; 44.5%)
		IV	111	35.9% (27.8%; 46.3%)	8.0% (4.1%; 15.7%)	8.3% (4.2%; 16.2%)	179	31.2% (25.0%; 38.9%)	11.8% (7.7%; 18.1%)	7.4% (3.7%; 14.6%)
		X/NA	189	38.2% (31.7%; 46.1%)	15.6% (10.7%; 22.7%)	10.9% (6.6%; 17.9%)	127	36.9% (29.2%; 46.7%)	16.4% (10.6%; 25.2%)	13.0% (7.7%; 22.0%)
Other and unspecified	**2004-2009**	All	243	40.3% (34.4%; 47.2%)	25.5% (20.2%; 32.2%)	20.9% (15.9%; 27.4%)	262	34.4% (29.0%; 40.9%)	19.4% (14.9%; 25.2%)	15.5% (11.1%; 21.7%)
		I	19	N<50	N<50	N<50	19	N<50	N<50	N<50
		II	18	N<50	N<50	N<50	26	N<50	N<50	N<50
		III	28	N<50	N<50	N<50	28	N<50	N<50	N<50
		IV	43	N<50	N<50	N<50	46	N<50	N<50	N<50
		X/NA	135	36.8% (29.3%; 46.2%)	22.8% (16.2%; 32.0%)	18.7% (12.7%; 27.7%)	143	39.9% (32.5%; 49.1%)	22.8% (16.4%; 31.5%)	17.3% (11.1%; 26.8%)
	2010-2014	All	327	38.6% (33.5%; 44.5%)	20.2% (15.9%; 25.6%)	17.0% (12.9%; 22.4%)	328	36.2% (31.2%; 42.0%)	21.5% (17.1%; 27.0%)	17.8% (13.5%; 23.5%)
		I	20	N<50	N<50	N<50	14	N<50	N<50	N<50
		II	32	N<50	N<50	N<50	17	N<50	N<50	N<50
		III	24	N<50	N<50	N<50	14	N<50	N<50	N<50
		IV	62	26.5% (17.5%; 40.1%)	13.5% (7.1%; 25.5%)	10.9% (5.3%; 22.5%)	85	24.5% (16.8%; 35.7%)	9.5% (4.9%; 18.6%)	6.3% (2.6%; 15.2%)
		X/NA	189	38.5% (31.9%; 46.5%)	19.9% (14.5%; 27.5%)	17.5% (12.0%; 25.4%)	198	36.2% (29.9%; 43.8%)	21.9% (16.2%; 29.5%)	18.2% (12.6%; 26.3%)
	2015-2019	All	433	38.1% (33.6%; 43.1%)	24.4% (20.3%; 29.3%)	17.5% (13.5%; 22.5%)	368	34.2% (29.5%; 39.7%)	20.2% (16.2%; 25.3%)	15.7% (11.8%; 20.8%)

Location	Period	Stage	Males				Females			
				Net Survival Probability				Net Survival Probability		
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	28	N<50	N<50	N<50	24	N<50	N<50	N<50
		II	32	N<50	N<50	N<50	27	N<50	N<50	N<50
		III	38	N<50	N<50	N<50	27	N<50	N<50	N<50
		IV	85	26.8% (18.8%; 38.2%)	13.3% (7.6%; 23.4%)	3.8% (1.2%; 12.6%)	87	22.3% (15.0%; 33.1%)	9.8% (5.2%; 18.7%)	6.3% (2.8%; 14.2%)
		X/NA	250	35.9% (30.2%; 42.7%)	21.9% (16.9%; 28.4%)	17.5% (12.6%; 24.2%)	203	32.6% (26.5%; 40.0%)	18.4% (13.4%; 25.5%)	14.2% (9.3%; 21.7%)
	2020-2024	All	391	36.0% (31.4%; 41.3%)	22.2% (18.0%; 27.4%)	17.6% (13.1%; 23.7%)	347	28.5% (24.0%; 33.8%)	17.3% (13.3%; 22.4%)	13.9% (9.9%; 19.6%)
		I	42	N<50	N<50	N<50	21	N<50	N<50	N<50
		II	30	N<50	N<50	N<50	28	N<50	N<50	N<50
		III	51	43.1% (31.2%; 59.5%)	22.2% (12.1%; 40.7%)	FU<5y	40	N<50	N<50	N<50
		IV	119	15.6% (10.2%; 23.7%)	8.2% (4.4%; 15.1%)	8.4% (4.5%; 15.5%)	123	15.0% (9.8%; 23.0%)	4.2% (1.8%; 9.8%)	4.5% (1.9%; 10.4%)
		X/NA	149	34.5% (27.4%; 43.4%)	21.7% (15.3%; 30.6%)	16.9% (10.4%; 27.6%)	135	25.7% (19.1%; 34.6%)	16.3% (10.5%; 25.2%)	12.3% (6.8%; 22.3%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

6.1. Cancer of the biliary system mortality: by region

6.1.1. Cancer of the biliary system mortality by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Males																						
Belgium	0	0	0	0	1	0	1	1	7	9	11	41	66	98	131	162	101	75	33	4	741	14.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.3]	[0.3]	[1.8]	[2.4]	[2.8]	[10.2]	[17.6]	[30.8]	[49.2]	[79.7]	[80.9]	[94.1]	[105.3]	[66.0]	[12.9]	(13.0; 15.0)
Brussels	0	0	0	0	0	0	0	0	1	3	0	3	4	10	11	14	8	5	2	0	61	17.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[6.8]	[0.0]	[8.5]	[13.9]	[46.8]	[65.4]	[110.9]	[99.5]	[99.9]	[86.8]	[0.0]	[10.0]	(12.6; 21.3)
Flanders	0	0	0	0	0	0	0	1	4	3	5	25	34	52	62	81	54	48	27	2	398	11.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.8]	[1.4]	[2.2]	[10.3]	[14.9]	[26.5]	[37.8]	[62.1]	[65.5]	[89.2]	[129.8]	[50.4]	[11.9]	(10.7; 13.1)
Wallonia	0	0	0	0	1	0	1	0	2	3	6	13	28	36	58	67	39	22	4	2	282	17.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.8]	[0.0]	[1.7]	[2.5]	[4.8]	[10.4]	[23.9]	[35.7]	[67.9]	[111.1]	[113.4]	[105.1]	[48.6]	[128.7]	[15.7]	(15.6; 19.8)
Females																						
Belgium	0	1	0	0	0	0	0	0	1	8	14	15	28	46	65	68	61	83	34	8	432	6.3
	[0.0]	[0.3]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[2.2]	[3.6]	[3.8]	[7.3]	[13.6]	[21.9]	[27.7]	[35.0]	[62.0]	[48.0]	[38.4]	[7.3]	(5.7; 6.9)
Brussels	0	0	0	0	0	0	0	0	0	0	3	1	3	3	0	4	1	7	2	0	24	4.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[7.8]	[2.9]	[9.9]	[12.0]	[0.0]	[22.2]	[7.8]	[71.4]	[35.3]	[0.0]	[3.8]	(2.6; 6.2)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	1	0	0	0	0	0	0	1	2	9	6	19	24	37	44	48	47	20	3	261	6.3
	[0.0]	[0.6]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.0]	[4.0]	[2.5]	[8.3]	[11.9]	[21.1]	[29.3]	[43.9]	[55.1]	[45.5]	[24.5]	[7.6]	(5.5; 7.1)
Wallonia	0	0	0	0	0	0	0	0	0	6	2	8	6	19	28	20	12	29	12	5	147	6.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[5.1]	[1.6]	[6.3]	[4.9]	[17.0]	[28.0]	[25.8]	[23.1]	[75.0]	[56.6]	[77.1]	[7.8]	(5.7; 8.0)

7.1. Cancer of the biliary system mortality trends: by region

7.1.1. Cancer of the biliary system mortality trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	473	464	470	495	528	509	549	586	598	604	595	671	663	658	683	684	699	760	700	741		
	CR	9.3	9.1	9.1	9.6	10.1	9.7	10.3	10.9	11.0	11.1	10.9	12.2	12.0	11.8	12.2	12.2	12.3	13.4	12.3	12.9		
	ESR2013	12.1	12.0	12.1	12.4	12.7	12.3	12.7	13.2	13.3	13.5	12.9	14.4	14.1	13.6	14.0	13.7	13.8	14.8	13.4	14.0	0.9 (0.6; 1.1)	2004-2023
																						1.4 (1.0; 1.8)	2004-2015
																						0.1 (-0.5; 0.8)	2016-2023
Brussels	**N**	48	60	47	47	52	47	62	52	56	59	59	57	59	61	60	59	63	59	58	61		
	CR	10.0	12.4	9.6	9.5	10.3	9.1	11.8	9.6	10.1	10.5	10.4	10.0	10.2	10.5	10.2	10.0	10.5	9.8	9.7	10.0		
	ESR2013	15.3	18.5	15.1	15.0	15.4	14.5	19.6	13.9	15.9	18.0	17.9	15.3	17.0	17.3	16.2	16.4	17.6	15.9	15.3	17.0	0.2 (-0.5; 1.0)	2004-2023
Flanders	**N**	239	226	248	245	272	278	290	326	318	311	321	315	321	343	324	370	354	390	390	398		
	CR	8.1	7.6	8.3	8.1	8.9	9.1	9.4	10.5	10.1	9.9	10.1	9.9	10.0	10.6	10.0	11.3	10.8	11.8	11.8	11.9		
	ESR2013	10.1	9.9	10.4	10.1	10.9	10.9	10.9	12.1	11.6	11.2	11.3	11.0	11.1	11.4	10.7	12.0	11.1	12.1	11.9	11.9	1.0 (0.7; 1.4)	2004-2023
																						1.7 (0.9; 2.5)	2004-2013
																						-1.4 (-2.9; 0.2)	2014-2017
																						1.6 (0.3; 2.9)	2018-2023
Wallonia	**N**	186	178	175	203	204	184	197	208	224	234	215	299	283	254	299	255	282	311	252	282		

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
	CR	11.3	10.8	10.6	12.2	12.2	10.9	11.6	12.1	13.0	13.5	12.3	17.1	16.1	14.4	16.9	14.4	15.8	17.4	14.1	15.7		
	ESR2013	15.1	14.3	15.0	16.0	15.9	14.5	14.7	15.0	16.2	16.9	14.9	21.3	19.6	17.5	20.2	16.5	18.2	20.0	16.2	17.7	1.4 (0.6; 2.1)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Cancer of the biliary system mortality trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	373	369	394	397	400	431	450	456	424	446	420	431	408	428	391	475	419	476	440	432		
	CR	7.0	6.9	7.3	7.3	7.4	7.9	8.1	8.2	7.5	7.9	7.4	7.6	7.1	7.4	6.8	8.2	7.2	8.1	7.5	7.3		
	ESR2013	7.0	6.8	7.1	7.0	6.9	7.4	7.8	7.6	6.9	7.3	6.8	6.8	6.4	6.7	6.0	7.2	6.3	7.2	6.5	6.3	-0.5 (-1.0; -0.1)	2004-2023
Brussels	**N**	37	33	58	38	52	29	53	46	52	38	41	51	39	42	32	43	28	50	42	24		
	CR	7.1	6.3	11.0	7.1	9.6	5.3	9.4	8.0	8.9	6.4	6.9	8.5	6.4	6.9	5.2	7.0	4.5	8.1	6.7	3.8		
	ESR2013	7.1	6.2	11.1	7.5	10.2	5.6	10.3	9.3	9.5	7.5	8.1	10.3	7.7	7.7	5.7	8.0	5.4	9.6	8.5	4.4	-1.1 (-3.1; 0.9)	2004-2023
Flanders	**N**	195	217	211	202	203	259	235	243	221	259	235	229	223	231	241	280	244	266	243	261		
	CR	6.4	7.1	6.8	6.5	6.5	8.2	7.4	7.6	6.9	8.0	7.2	7.0	6.8	7.0	7.3	8.4	7.3	7.9	7.2	7.6		
	ESR2013	6.4	7.0	6.6	6.1	6.1	7.6	7.0	6.8	6.2	7.2	6.4	6.0	5.8	6.0	6.3	7.0	6.0	6.6	5.8	6.3	-0.4 (-1.0; 0.1)	2004-2023
Wallonia	**N**	141	119	125	157	145	143	162	167	151	149	144	151	146	155	118	152	147	160	155	147		
	CR	8.1	6.8	7.1	8.9	8.2	8.0	9.0	9.2	8.3	8.1	7.9	8.2	7.9	8.4	6.4	8.2	7.9	8.6	8.3	7.8		
	ESR2013	8.0	6.7	7.0	8.4	7.6	7.7	8.7	8.6	7.7	7.6	7.2	7.4	7.2	7.7	5.6	7.4	7.2	7.8	7.3	6.8	-0.5 (-1.3; 0.2)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026